Check-Cap (NASDAQ:CHEK) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK opened at $1.86 on Friday. The firm has a fifty day moving average of $1.95 and a 200-day moving average of $2.13. The company has a market cap of $10.88 million, a price-to-earnings ratio of -0.62 and a beta of 0.40. Check-Cap has a 1 year low of $1.77 and a 1 year high of $4.63.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.